Shire plc / Lumena Pharmaceuticals, Inc.

Cholestatic Liver Disease (Alagille syndrome, PFIC, PBC, PSC)

Disease Overview

Cholestatic liver diseases are conditions where bile flow from the liver is impaired, causing toxic bile acid accumulation, severe pruritus (itch), jaundice, and progressive hepatic injury. Rare pediatric forms (Alagille syndrome, PFIC) and adult autoimmune forms (primary biliary cholangitis, primary sclerosing cholangitis) share unmet need: ASBT inhibition reduces gut bile acid reabsorption to relieve symptoms and potentially slow progression.

Competitive Landscape

At the time of the 2014 Shire-Lumena deal, the cholestatic-liver landscape was thinly competitive. Adult PBC was anchored by ursodiol (UDCA, generic) as standard of care, with Intercept's obeticholic acid (Ocaliva) approaching FDA approval (granted 2016). PSC had no approved disease-modifying therapy. Pediatric Alagille and PFIC had only symptomatic management — antihistamines, rifampin, ursodiol, and ultimately partial external biliary diversion or liver transplant. ASBT/IBAT inhibitors represented a novel class. Shire's $260M upfront positioned it as the first big pharma to consolidate the class, but the strategic logic dissolved when Takeda acquired Shire in 2019 and divested the program. LUM001 (maralixibat) was bought back by Mirum Pharmaceuticals in 2018 for $120M, ultimately winning FDA approval as Livmarli for Alagille syndrome (Sept 2021) and PFIC (March 2024). Albireo's Bylvay (odevixibat), another IBAT inhibitor, won approval for PFIC in 2021 and Alagille in 2024, creating a two-horse class race. Volixibat (LUM002) is now in Mirum's pipeline for cholestatic pruritus indications.